Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.31
+0.08000.12%
Volume:192.27K
Turnover:12.59M
Market Cap:12.62B
PE:172.33
High:66.02
Open:65.54
Low:65.05
Close:65.23
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.71
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.00
PE(LYR):36.28

Loading ...

BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition

MT Newswires Live
·
Apr 07

What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders

Simply Wall St.
·
Mar 31

Exploring High Growth Tech Stocks In The US Market March 2026

Simply Wall St.
·
Mar 27

Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness

TIPRANKS
·
Mar 17

BioMarin halts Phase 2 VOXZOGO dosing and enrollment in Turner syndrome, SHOX-deficiency and ACAN-deficiency trials

Reuters
·
Mar 16

Biomarin: Decision to Discontinue Following Occurrence of Several Slipped Capital Femoral Epiphysis Events in 2 Ongoing Investigator-Sponsored Trials

THOMSON REUTERS
·
Mar 16

Biomarin Pharmaceutical - Phase 2 Canopy Trials of Voxzogo in Noonan Syndrome, Idiopathic Short Stature to Continue - SEC Filing

THOMSON REUTERS
·
Mar 16

BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2

Reuters
·
Mar 12

BioMarin Pharmaceutical Is Maintained at Buy by B of A Securities

Dow Jones
·
Mar 11

Biomarin Pharmaceutical Inc : Bofa Global Research Cuts Price Objective to $85.00 From $97.00

THOMSON REUTERS
·
Mar 11

BioMarin price target lowered to $85 from $97 at BofA

TIPRANKS
·
Mar 11

U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, Oracle

Reuters
·
Mar 11

PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN)

Simply Wall St.
·
Mar 11

Absci names Ransi Somaratne chief medical officer as Andreas Busch set to retire

Reuters
·
Mar 07

Camp4 Therapeutics FY 2025 research and collaboration revenue rises 436.5% to USD 3.5 million

Reuters
·
Mar 06